Indian pharmaceutical market registers 9 percent growth in September: IQVIA Report
New Delhi: The Indian Pharmaceutical Market (IPM) has witnessed a spike of nine percent in September 2023, according to International Quality and Value Institute Advisors (IQVIA), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
As per the report, the Total Sales Audit (TSA) was valued at Rs 208,843 crore with a growth of 10 percent as of Moving Annual Turnover (MAT) September and Rs 19,174 crore for September month with a growth of 9 percent was recorded.
On the other hand, the Stockist Sales Audit (SSA) has been valued at Rs 176,513 crore with a growth of 10 percent as of MAT April and Rs 16,251 crore for April month with a growth of 11%.
In addition, study findings mentioned that in September 2023, Abbott, Cipla, Mankind, Alkem, Macleods, and Aristo demonstrated an increase in their market share compared to August 2023, out of the top 10 firms.
The survey also mentioned that Sun, Intas, Lupin, and Torrent showed a dip in their market shares in September 2023 compared to August 2023.
Among the top ten firms for the month, in accordance with the Total Sales Audit (TSA), Aristo has posted the highest growth followed by Macleods on the Month level, while on the MAT level, Macleods followed by Intas are the fastest growing.
Furthermore, as per the Stockist Sales Audit (SSA), among the top ten firms for the month, Aristo has posted the highest growth followed by Macleods on the Month level, while on the MAT level, Mankind and Macleods are the fastest growing.
Among the top 11–20 companies in September 2023, DRL, Zydus, IPCA, Glenmark, Micro, and Alembic have shown improvement in market share for Sep’23 as compared to Aug’23 while GSK, Emcure, USV, and Sanofi have reflected a dip in market share for Sep’23 as compared to Aug’23.
In regards to the medicine brands, the report found that Monocef is the leading brand in the pharmaceutical industry with 81 Crs of sales and a market share of ~0.42% for the month. Among the top 10 brands, Foracort has shown the highest growth followed by Monocef for the month.
In addition to the aforementioned, the report noted the following about the top 25 products as of Sep'23 Month (in comparison to Aug'23 Month):
• Monocef has gained the No. 1 position at the monthly level with a growth of 21%
• Amongst the top 20 Brands, Zerodol SP observed highest growth of 30%
• Foracort & Clavam gained 1 rank each to secure 4th & 8th position, respectively
• Zerodol- SP gained 2 ranks to secure the 12th position
• Calpol gained 3 ranks to secure 9th position with a growth of 10%
• Azithral, Duolin, Aciloc & Moxikind CV gained 5 ranks to secure 16th, 20th, 23rd, 24th position with a growth of 4%, 12%, 15% & 14%
• Mikacin gained 6 ranks to secure 25th position with a growth of 18%
• Budecort gained 16 ranks to secure 21st position with a growth of 14%
Furthermore, in line with the top therapy trends, the report highlighted the following facts:
• In Cardiac, Enoxaparin posted 18% growth which is highest amongst top therapies.
• In Anti-Infectives, Ceftriaxone+Sulbactam posted the highest growth of 24%
• In Gastrointestinal, Milk of Mag and comb. a subgroup posted the highest growth of 26%
• In Anti-diabetic, the Metformin+Sitagliptin subgroup has posted the highest growth of 18%
• In VMN therapy, food supplements are the top contributing subgroup with 214 Cr of sales posted growth of 9%
• In the Respiratory market, Formoterol+Budesonide posted the highest growth of 21%
• In Pain market, paracetamol oral solids, liquids & inj contributed ~ 223 Crs of sales with 11%,-6% & 14% growth, respectively
• In the Derma market, Emollient Protectives registered the highest sales of 125 Cr in the Derma market with 16% growth while the highest growth of 22% is observed in Sunscreens.
• In Neuro therapy, Levetiracetam is the top contributing subgroup with 91 Cr of sales posted growth of 11%
• In Gynaec therapy, conv iron solids, liquids, and inj. together have contributed ~320 Cr of sales to the entire therapy
• In Urology therapy, Dutasteride+Silodosin posted the highest growth of 24%
• In ophthalmic therapy, Methyl Cellulose registered the highest sales of 43 Cr in ophthalmic therapy with -8% growth while the highest growth of 16% is observed in Macrogol+Propyl. Gly and Comb.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd